



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 135515

TO: Alton Pryor
Location: REM 4A39
Art Unit: 1616
October 19, 2004

4010

Case Serial Number: 10/049821

From: P. Sheppard
Location: Remsen Building
Phone: (571) 272-2529

sheppard@uspto.gov

Search Notes

=> fil hcaplus
 FILE 'HCAPLUS' ENTERED AT 15:28:08 ON 19 OCT 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Oct 2004 VOL 141 ISS 17
 FILE LAST UPDATED: 18 Oct 2004 (20041018/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=>
 =>

=> d stat que
 L3 STR



VAR G1=C/N
 VAR G2=C/N/O/S
 REP G3=(1-4) C
 REP G5=(2-4) A
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE
 L9 92 SEA FILE=REGISTRY SSS FUL L3
 L10 2 SEA FILE=REGISTRY ABB=ON PLU=ON ("LAURIC DIETHANOLAMIDE"/CN
 OR "LAURIC DIETHANOLAMINE"/CN)
 L11 37 SEA FILE=HCAPLUS ABB=ON PLU=ON L9
 L12 SEL PLU=ON L10 1- CHEM : 101 TERMS
 L13 7054 SEA FILE=HCAPLUS ABB=ON PLU=ON L12
 L14 7142 SEA FILE=HCAPLUS ABB=ON PLU=ON L13 OR LAUR?(A)DIETHANOL?

L15 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L11 AND L14

=>
=>

=> d ibib abs hitstr l15 1

L15 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:152517 HCAPLUS
DOCUMENT NUMBER: 134:183534
TITLE: Percutaneous absorption agents containing melatonin agonists
INVENTOR(S): Suzuki, Yasuyuki; Iga, Katsumi; Miyamoto, Masaomi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|--|------------|
| WO 2001013950 | A1 | 20010301 | WO 2000-JP5525 | 20000818 |
| W: | | | AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | |
| RW: | | | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | |
| JP 2001131089 | A2 | 20010515 | JP 2000-254233 | 20000818 |
| EP 1214944 | A1 | 20020619 | EP 2000-953481 | 20000818 |
| R: | | | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | |
| PRIORITY APPLN. INFO.: | | | JP 1999-234106 | A 19990820 |
| | | | WO 2000-JP5525 | W 20000818 |

OTHER SOURCE(S): MARPAT 134:183534

AB Percutaneous absorption agents which make it possible to absorb compds. having a melatonin receptor agonism via a convenient administration system, have favorable blood concentration passage characteristics and can exert a therapeutic effect on a disease caused by a decrease in melatonin at night. The compns. comprise melatonin agonists and ≥ 1 compds. selected from the group consisting of fatty acid esters, polyhydric alcs., and nonionic surfactants. A patch was prepared containing (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide 7.5, DuroTak 87-2979 47.5, **lauric acid diethanolamide** 5.0, iso-Pr myristate 20, and propylene glycol 20 %.


IT 326793-94-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(transdermal prepn. containing melatonin agonists for treatment of sleep disorders)

RN 326793-94-6 HCAPLUS

CN Acetamide, N-[2-[(8S)-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 196597-26-9


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(transdermal preps. containing melatonin agonists for treatment of sleep disorders)

RN 196597-26-9 HCAPLUS

CN Propanamide, N-[2-[(8S)-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 120-40-1, Lauric acid diethanolamide

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transdermal preps. containing melatonin agonists for treatment of sleep disorders)

RN 120-40-1 HCAPLUS

CN Dodecanamide, N,N-bis(2-hydroxyethyl)- (6CI, 8CI, 9CI) (CA INDEX NAME)



REFERENCE COUNT:

14

THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> □

=> d stat que nos 122

L3 STR
L9 92 SEA FILE=REGISTRY SSS FUL L3
L10 2 SEA FILE=REGISTRY ABB=ON PLU=ON ("LAURIC DIETHANOLAMIDE"/CN
OR "LAURIC DIETHANOLAMINE"/CN)
L11 37 SEA FILE=HCAPLUS ABB=ON PLU=ON L9
L12 SEL PLU=ON L10 1- CHEM : 101 TERMS
L13 7054 SEA FILE=HCAPLUS ABB=ON PLU=ON L12

L14 7142 SEA FILE=HCAPLUS ABB=ON PLU=ON L13 OR LAUR?(A)DIETHANOL?
 L15 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L11 AND L14
 L16 158 SEA FILE=REGISTRY ABB=ON PLU=ON (MELATONIN/BI OR MELATONINE/B
 I)
 L17 13472 SEA FILE=HCAPLUS ABB=ON PLU=ON L16 OR ?MELATONIN?
 L21 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L14 AND L17
 L22 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L21 NOT L15

=>
 =>

=> d ibib abs hitstr l22 1-2

L22 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2000:14983 HCAPLUS
 DOCUMENT NUMBER: 132:83650
 TITLE: Solid dispersed preparation of poorly water-soluble
 drug containing oil, fatty acid or mixtures thereof
 INVENTOR(S): Lee, Beom Jin
 PATENT ASSIGNEE(S): Won Jin Biopharma Co., Ltd., S. Korea
 SOURCE: PCT Int. Appl., 67 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2000000179 | A1 | 20000106 | WO 1999-KR341 | 19990628 |
| W: AU, CA, CN, JP, US | | | | |
| RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| KR 2000006503 | A | 20000125 | KR 1999-24437 | 19990626 |
| AU 9946556 | A1 | 20000117 | AU 1999-46556 | 19990628 |
| PRIORITY APPLN. INFO.: | | | KR 1998-24563 | A 19980627 |
| | | | KR 1999-24437 | A 19990626 |
| | | | WO 1999-KR341 | W 19990628 |

AB Disclosed is a solid dispersed preparation for poorly water-soluble drugs, which is prepared by dissolving or dispersing the poorly water-soluble drugs in an oil, a fatty acid or a mixture thereof, mixing the solution or dispersion in a water-soluble polyol matrix and drying the mixture. The solid dispersed preparation can be formulated into a power formulation or a granule formulation. The solid dispersed preparation is improved in the solubility of poorly water-soluble drugs

in the gastro-intestinal tract, resulting in a great increase in the bioavailability of the drugs. In addition, the solid dispersed preparation gives the pharmaceutical solns. to the problems that the conventional semi-solid or liquid prepns. possess, enabling medicinally effective, poorly water-soluble compds. to be formulated, molded and processed, quickly and in an economically favorable manner without use of any organic solvent. Examples are given for emulsions containing mixts. of waxes, oils, and aqueous phase.

IT 73-31-4, Melatonin 120-40-1D, Lauric acid diethanolamide, coco acyl derivs.

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(solid dispersed preparation of poorly water-soluble drug containing oils and

fatty

acid or mixts.)


RN 73-31-4 HCAPLUS

CN Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 120-40-1 HCAPLUS

CN Dodecanamide, N,N-bis(2-hydroxyethyl)- (6CI, 8CI, 9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:268388 HCAPLUS

DOCUMENT NUMBER: 128:326524

TITLE: Permeation enhancers for transdermal drug delivery compositions, devices, and methods

INVENTOR(S): Lee, Eun Soo; Yum, Su Il

PATENT ASSIGNEE(S): Alza Corp., USA

SOURCE: PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 9817315 | A2 | 19980430 | WO 1997-US18956 | 19971023 |
| WO 9817315 | A3 | 19980702 | | |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| CA 2264687 | AA | 19980430 | CA 1997-2264687 | 19971023 |
| AU 9749907 | A1 | 19980515 | AU 1997-49907 | 19971023 |
| EP 934078 | A2 | 19990811 | EP 1997-912815 | 19971023 |
| EP 934078 | B1 | 20021218 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| JP 2001502693 | T2 | 20010227 | JP 1998-519563 | 19971023 |
| AT 229817 | E | 20030115 | AT 1997-912815 | 19971023 |
| ES 2191834 | T3 | 20030916 | ES 1997-912815 | 19971023 |
| PRIORITY APPLN. INFO.: US 1996-30424P P 19961024 | | | | |
| WO 1997-US18956 W 19971023 | | | | |


AB The present invention is directed to the transdermal administration of at least one drug together with a suitable amount of a permeation enhancer comprising monoalkyl ethers of polyethyleneglycol and their alkyl or aryl carboxylic acid esters and carboxymethyl ethers. The invention includes a

transdermal drug delivery device comprising a matrix adapted to be placed in drug-and-permeation enhancer-transmitting relation with a skin site. The matrix contains sufficient amts. of the permeation enhancer and drug, in combination, to continuously administer drug to the systemic circulation of a patient at a therapeutically effective rate. The invention is also directed to compns. and methods for transdermal administration of at least one drug together with a permeation enhancer of this invention, alone or in combination with other enhancers. Laureth-4 (30 weight%) alone exhibited about a 4-fold increase in testosterone permeation compared to a sample without any permeation enhancer.

IT 73-31-4, Melatonin 120-40-1, Dodecanamide,
N,N-bis(2-hydroxyethyl)-
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (permeation enhancers for transdermal drug delivery compns.)
RN 73-31-4 HCAPLUS
CN Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 120-40-1 HCAPLUS
CN Dodecanamide, N,N-bis(2-hydroxyethyl)- (6CI, 8CI, 9CI) (CA INDEX NAME)



=> □

=> d stat que nos

L3 STR
L9 92 SEA FILE=REGISTRY SSS FUL L3
L11 37 SEA FILE=HCAPLUS ABB=ON PLU=ON L9
L31 11 SEA FILE=HCAPLUS ABB=ON PLU=ON L11 (L) (?MEDICI? OR ?THERAP?
OR ?DRUG? OR ?PHARM?)
L33 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L31 AND SLEEP

=> d ibib abs hitstr 133 1

L33 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:795635 HCAPLUS
DOCUMENT NUMBER: 132:40535
TITLE: Pharmaceutical composition for treating or preventing
sleep disorders
INVENTOR(S): Ohkawa, Shigenori; Miyamoto, Masaomi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|------------|
| WO 9963977 | A2 | 19991216 | WO 1999-JP3057 | 19990608 |
| WO 9963977 | A3 | 20010329 | | |
| W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2332521 | AA | 19991216 | CA 1999-2332521 | 19990608 |
| AU 9940605 | A1 | 19991230 | AU 1999-40605 | 19990608 |
| JP 2000063272 | A2 | 20000229 | JP 1999-160568 | 19990608 |
| JP 3509637 | B2 | 20040322 | | |
| EP 1100508 | A2 | 20010523 | EP 1999-923960 | 19990608 |
| EP 1100508 | B1 | 20030827 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| AT 247967 | E | 20030915 | AT 1999-923960 | 19990608 |
| US 6348485 | B1 | 20020219 | US 2000-700405 | 20001114 |
| PRIORITY APPLN. INFO.: | | | | |
| | | | JP 1998-160270 | A 19980609 |
| | | | WO 1999-JP3057 | W 19990608 |

AB The present invention provides a pharmaceutical composition for treating or preventing **sleep** disorders which comprises (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide (I) in combination with at least 1 active component selected from zolpidem, zopiclone, triazolam and brotizolam. Thus, I was obtained in a series of steps starting from 2,3-dihydrobenzofuran-5-carbaldehyde. Tablets were prepared from I 10.0, lactose 60.0, corn starch 35.0, gelatin 3.0, and Mg stearate 2.0 g. Treatment with compound I (0.003 mg/kg, p.o.) had no significant effects on the latency of any **sleep** stages. Treatment with triazolam alone (0.03 mg/kg) did not affect general behavior and it did not cause ataxia and sedation as such were seen when high doses of triazolam are given. Co-administration of I and triazolam shortened the latencies of deep slow wave **sleep**, stage 3 and stage 4, and it significantly shortened the latency of the stage 4 **sleep**. The co-administration also had no significant effects on general behavior of monkeys.


IT 196597-26-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (pharmaceutical composition for treating or preventing **sleep** disorders)

RN 196597-26-9 HCAPLUS

CN Propanamide, N-[2-[(8S)-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



=>